Galmed Pharmaceuticals (GLMD) Research & Development (2013 - 2026)
Galmed Pharmaceuticals (GLMD) posted quarterly Research & Development of $1.4 million for Q1 2026, up 114.51% year-over-year from $634000.0 in Q1 2025, and up 151.97% quarter-over-quarter from -$2.6 million in Q4 2025.
Galmed Pharmaceuticals (GLMD) Research & Development (2013 - 2026) Analysis & Trends
Galmed Pharmaceuticals' Research & Development history runs 14 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- In Q1 2026, Research & Development rose 114.51% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $887000.0 (up 491.33% YoY), while the FY2025 annual figure was $161000.0, up 6.62% from the prior year.
- Research & Development for Q1 2026 stood at $1.4 million, up from -$2.6 million in the prior quarter.
- The five-year high for Research & Development was $4.2 million in Q3 2022, with the low at -$2.6 million in Q4 2025.
- The 5-year median for Research & Development is $809000.0 (2023), against an average of $780588.2.
- The sharpest annual moves came in 2023 and 2024: Research & Development surged 737.06% in 2023, then sank 256.65% in 2024.
- Galmed Pharmaceuticals' Research & Development stood at $1.4 million in 2022, then declined by 18.65% to $1.1 million in 2023, then tumbled by 256.65% to -$1.8 million in 2024, then plunged by 49.03% to -$2.6 million in 2025, then soared by 151.97% to $1.4 million in 2026.
- Business Quant data shows GLMD's Research & Development at $1.4 million in Q1 2026, -$2.6 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Galmed Pharmaceuticals | 2.39 Mn | -9.49 Mn | - | 1.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.36 Mn |
| Dec 31, 2025 | -2.62 Mn |
| Sep 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 1.06 Mn |
| Mar 31, 2025 | 634,000.00 |
| Dec 31, 2024 | -1.76 Mn |
| Sep 30, 2024 | 738,000.00 |
| Jun 30, 2024 | 534,000.00 |
| Mar 31, 2024 | 635,000.00 |
| Dec 31, 2023 | 1.12 Mn |
| Sep 30, 2023 | 556,000.00 |
| Jun 30, 2023 | 809,000.00 |
| Mar 31, 2023 | 1.08 Mn |
| Dec 31, 2022 | 1.38 Mn |
| Sep 30, 2022 | 4.24 Mn |
| Jun 30, 2022 | 2.58 Mn |
| Mar 31, 2022 | -170,000.00 |
| Dec 31, 2021 | 6.26 Mn |
| Sep 30, 2021 | 6.54 Mn |
| Jun 30, 2021 | 7.04 Mn |